J Thromb Haemost:静脉血栓栓塞后的身体活动与复发风险以及死亡率的关系

2019-04-16 xing.T 网络

由此可见,该研究结果表明VTE事件发生前的习惯性体力活动不会影响复发风险。相比之下,经常活动的个体死亡风险较低,特别是在DVT后。

关于静脉血栓栓塞(VTE)后身体活动与主要并发症之间关系的数据十分有限。近日,血栓和凝血疾病权威杂志Journal of Thrombosis and Haemostasis上发表了一篇研究文章,该研究旨在从一般人群中招募的VTE患者中调查体育活动是否与复发风险和死亡率相关。

研究人员纳入了特罗姆瑟研究调查4-6(1994-1995、2001-2002和2007-2008)中的VTE患者(n=786),根据调查报告的活动水平对体力活动数据分为两组(非活动组:每周<1小时,活动组:每周≥1小时)。在2015年12月31日之前记录复发性VTE和全因死亡率。研究人员使用Cox回归模型计算复发和全因死亡率的风险比(HRs),以非活性组为参考。

随访期间,共有139例复发,395例死亡。体力活动与男性(模型2的HR:1.48,95%可信区间(CI)0.83-2.65)或女性(模型2的HR:0.95,95%CI为0.52-1.74)复发风险无关。相比之下,体育活动与10年随访期间死亡风险降低28%相关(模型3的HR:0.72,95%CI为0.57-0.91)。首次深静脉血栓形成患者(DVT; 模型2的HR:0.59,95%CI为0.44-0.79)的负相关性强于肺栓塞患者(模型3的HR:0.87,95%CI为0.61-1.26)。

由此可见,该研究结果表明VTE事件发生前的习惯性体力活动不会影响复发风险。相比之下,经常活动的个体死亡风险较低,特别是在DVT后。 

原始出处:

Line H. Evensen.et al.Physical activity and risk of recurrence and mortality after incident venous thromboembolism.Journal of Thrombosis and Haemostasis.2019.https://onlinelibrary.wiley.com/doi/10.1111/jth.14449

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1955428, encodeId=89641955428e2, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Jul 14 03:16:00 CST 2019, time=2019-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008416, encodeId=d62e200841659, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sat Jul 13 10:16:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905525, encodeId=2fb11905525d5, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Wed Mar 18 07:16:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697887, encodeId=14f8169e88748, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon May 13 01:16:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410677, encodeId=c4a414106e7e3, content=<a href='/topic/show?id=f22193211c8' target=_blank style='color:#2F92EE;'>#身体活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93211, encryptionId=f22193211c8, topicName=身体活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=746d2763332, createdName=smlt2009, createdTime=Thu Apr 18 07:16:00 CST 2019, time=2019-04-18, status=1, ipAttribution=)]
    2019-07-14 xue8602
  2. [GetPortalCommentsPageByObjectIdResponse(id=1955428, encodeId=89641955428e2, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Jul 14 03:16:00 CST 2019, time=2019-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008416, encodeId=d62e200841659, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sat Jul 13 10:16:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905525, encodeId=2fb11905525d5, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Wed Mar 18 07:16:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697887, encodeId=14f8169e88748, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon May 13 01:16:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410677, encodeId=c4a414106e7e3, content=<a href='/topic/show?id=f22193211c8' target=_blank style='color:#2F92EE;'>#身体活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93211, encryptionId=f22193211c8, topicName=身体活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=746d2763332, createdName=smlt2009, createdTime=Thu Apr 18 07:16:00 CST 2019, time=2019-04-18, status=1, ipAttribution=)]
    2019-07-13 changfy
  3. [GetPortalCommentsPageByObjectIdResponse(id=1955428, encodeId=89641955428e2, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Jul 14 03:16:00 CST 2019, time=2019-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008416, encodeId=d62e200841659, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sat Jul 13 10:16:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905525, encodeId=2fb11905525d5, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Wed Mar 18 07:16:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697887, encodeId=14f8169e88748, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon May 13 01:16:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410677, encodeId=c4a414106e7e3, content=<a href='/topic/show?id=f22193211c8' target=_blank style='color:#2F92EE;'>#身体活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93211, encryptionId=f22193211c8, topicName=身体活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=746d2763332, createdName=smlt2009, createdTime=Thu Apr 18 07:16:00 CST 2019, time=2019-04-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1955428, encodeId=89641955428e2, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Jul 14 03:16:00 CST 2019, time=2019-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008416, encodeId=d62e200841659, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sat Jul 13 10:16:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905525, encodeId=2fb11905525d5, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Wed Mar 18 07:16:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697887, encodeId=14f8169e88748, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon May 13 01:16:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410677, encodeId=c4a414106e7e3, content=<a href='/topic/show?id=f22193211c8' target=_blank style='color:#2F92EE;'>#身体活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93211, encryptionId=f22193211c8, topicName=身体活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=746d2763332, createdName=smlt2009, createdTime=Thu Apr 18 07:16:00 CST 2019, time=2019-04-18, status=1, ipAttribution=)]
    2019-05-13 fusion
  5. [GetPortalCommentsPageByObjectIdResponse(id=1955428, encodeId=89641955428e2, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Jul 14 03:16:00 CST 2019, time=2019-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008416, encodeId=d62e200841659, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Sat Jul 13 10:16:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905525, encodeId=2fb11905525d5, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Wed Mar 18 07:16:00 CST 2020, time=2020-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697887, encodeId=14f8169e88748, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon May 13 01:16:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410677, encodeId=c4a414106e7e3, content=<a href='/topic/show?id=f22193211c8' target=_blank style='color:#2F92EE;'>#身体活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93211, encryptionId=f22193211c8, topicName=身体活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=746d2763332, createdName=smlt2009, createdTime=Thu Apr 18 07:16:00 CST 2019, time=2019-04-18, status=1, ipAttribution=)]

相关资讯

Clinical and translation gastroenterology: 非酒精性脂肪性肝炎引起的肝硬化住院患者静脉血栓栓塞的风险增加

肝硬化患者静脉血栓栓塞症(VTE)和门静脉血栓形成(PVT)的风险是显着增加的。非酒精性脂肪性肝炎(NASH)引起的肝硬化似乎特别易发生血栓。因此本项研究调查了因NASH肝硬化住院患者,以确定他们是否存在VTE风险增加。

J Thromb Haemost:接受新辅助化疗的癌症患者的静脉血栓栓塞!

由此可见,该综述发现在存在一些研究间变异中接受新辅助治疗的癌症患者VTE发生率相对较高,这值得在前瞻性研究中进一步评估。

Brit J Cancer:D-二聚体和hs-CRP水平预测CAT患者停止抗凝后静脉血栓栓塞复发

由此可见,该研究明确了hs-CRP和DD是CAT患者停用抗凝治疗后VTE复发的潜在生物标志物。风险适应策略可以识别可能从停止抗凝治疗中获益的低风险患者。

JAHA:儿童体重指数的变化与成年期静脉血栓栓塞的风险

由此可见,BMI持续高于平均水平的儿童在成年期患VTE的风险更高。虽然7-13岁的体重增加额外增加了VTE风险,但13岁时超重减轻会完全使升高的风险降至正常。

Chest:2007年至2016年间中国静脉血栓栓塞的住院和住院死亡率趋势

由此可见,VTE住院治疗稳步增加,死亡率持续下降。该研究为中国VTE的疾病负担提供了重要信息。

Oncologist:ROADMAP-CAT研究:肺腺癌相关的高凝标志增加COMPASS‐CAT RAM的VTE预测能力

新建立的肿瘤静脉血栓栓塞(VTE)风险评估模型COMPASS‐CAT RAM可以对肿瘤患者VTE风险进行相对精确的分层。近期有研究证实,将对诊断高凝有意义的标志与癌症相关血栓风险评估模型结合可进一步改善预测VTE的精确度,但在肺癌患者中应用的证据极少。为了确定对评估肺腺癌有症状的VTE最有价值的高凝标志,进一步改善COMPASS‐CAT RAM预测肺腺癌患者血栓风险的精确度,西腊的Syrigos教